

Special Issue

Protein Aggregation: Molecular Mechanisms, Determinants and Therapeutic Approaches Volume II

Message from the Guest Editor

MDPI's *Biomedicines* is setting up this Special Issue aiming to promote new findings focused on the current understanding of the molecular mechanisms and/or the determinants of macromolecular protein assemblies in both disease and in function, whether that is the formation of functional amyloids or the development of new aggregation-based technologies and strategies for therapeutics and nanomaterials. Our interest extends to studies that uncover new aspects of the cross-interaction interplay of protein assemblies with other biomolecules (e.g., nucleic acids, proteins, lipids) and the role of other factors in this process (pH, salts, post-translational modifications, and more). We aim to highlight recent advances in understanding the structural diversity of protein assemblies spanning from phase-separated biomolecular condensates to oligomers and polymorphic end-state amyloid fibrils and their interplay with proteostatic control mechanisms that regulate their formation and balance in a cellular context.

Guest Editor

Dr. Nikolaos N. Louros
VIB - KU Leuven, 3000 Leuven, Belgium

Deadline for manuscript submissions

closed (31 October 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/154063

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).